Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cellectis SA ( (CLLS) ) has shared an update.
On April 27, 2026, Cellectis announced that it is presenting new data on a TALE-based epigenetic editing platform at the American Society of Gene and Cell Therapy annual meeting in Boston, scheduled for May 11–15, 2026. The approach uses TALE-based epigenetic modulators to switch genes off without cutting or permanently altering DNA, positioning it as a potentially safer alternative to traditional genome editing.
The company reported that its high-throughput screening system identified potent TALE-based epigenetic modulators that achieved more than 90% durable knockdown of target genes in liver cells and T-cells, including a gene linked to T-cell dysfunction in cancer immunotherapy. By extending its gene-editing toolbox into epigenetic editing across multiple cell types, Cellectis underscores its innovation capabilities and reinforces its position in the competitive cell and gene therapy landscape ahead of its ASGCT poster presentation on May 13, 2026.
The most recent analyst rating on (CLLS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
The score is held back primarily by weak financial performance—persistent losses, renewed 2025 cash burn, and rising leverage—partly offset by a relatively constructive technical setup with the stock trading above several key moving averages. Valuation is constrained by negative earnings and the absence of a dividend.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. is a clinical-stage biotechnology company specializing in gene editing to develop cell and gene therapies, with a core focus on allogeneic, off-the-shelf CAR T immunotherapies for oncology and other indications. Headquartered in Paris with sites in New York and Raleigh, it is vertically integrated with in-house manufacturing and is listed on Nasdaq and Euronext Growth.
Average Trading Volume: 44,244
Technical Sentiment Signal: Buy
Current Market Cap: $280.4M
For an in-depth examination of CLLS stock, go to TipRanks’ Overview page.